home

Facebook, Napster pioneer Sean Parker sets up $250M immuno-oncology center

EVENTSfiercebiotech2016-04-14 09:42 Read   47

The billionaire Silicon Valley veteran Sean Parker will inject $250 million into the immuno-oncology research field in an effort to boost cancer survival rates.

SynteractHCR CRO 'looking for a $1.5B sale'

EVENTSfiercebiotech2016-04-14 09:03 Read   98

Privately-owned SynteractHCR is seeking a sale of its business and values itself at around $1.5 billion as its investor group owner looks to cash in on the major boon in the CRO sector.

Pluristem Continues to Strengthen its Position in Japan – Granted Two Key Cell Therapy Patents

EVENTSglobenewswire2016-04-13 17:29 Read   69

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, today announced that the Japan Patent Office has granted the Company two key patents addressing

Autoimmune Disease Diagnostics Market To Grow At 2.6% CAGR From 2014 to 2020: Grand View Research, Inc.

EVENTSglobenewswire2016-04-13 17:19 Read   115

According to the new report published by Grand View research, the global Autoimmune disease diagnostics market size will reach $ 5.74 Billion By 2020,growing at CAGR of 1.9 %, rising cases of autoimmune disease and the significant increase in healthcare expenditure have accelerated the launch of favorable government initiatives to encourage diagnostics and research organizations

SMC accepts three new drugs for NHS use, but bans two

EVENTSpharmatimes2016-04-13 16:58 Read   84

Three new medicines have been cleared for use by NHS Scotland by cost regulator the Scottish Medicines Consortium (SMC), bringing patients new options for breast cancer, fungal infection and warts.

National supply chain for med devices to save NHS millions

EVENTSpharmatimes2016-04-13 16:51 Read   96

NHS England has unveiled a new nationwide system for purchasing expensive medical devices which, it claims, could save the NHS over £60 million in its first two years, partly through reducing variation in cost.

Rite Aid opened 23 clinics in 2015, earned $30 billion as Walgreens takeover nears

EVENTShealthcarefinancenews2016-04-13 16:44 Read   69

Rite Aid earned nearly $166 million and opened 23 health clinics in 2015, the company announced in what may be its last full-year earnings report before its scheduled takeover by Walgreens.

Valeant wins new 10-K deadline from creditors, but gives up dealmaking freedom in return

EVENTSfiercepharma2016-04-13 14:56 Read   66

Valeant wins new 10-K deadline from creditors, but gives up dealmaking freedom in return

Incoming Bayer CEO looks to deals to beef up $1.7B animal health unit

EVENTSfiercepharma2016-04-13 14:13 Read   77

Bayer's incoming CEO Werner Baumann knows a thing or two about dealmaking, and he's ready to put his M&A smarts to good use. Baumann wants to build up the company's animal health unit through targeted acquisitions and partnerships once he takes the reins next month.

Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics

EVENTSregeneron2016-04-13 13:55 Read   122

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Intellia Therapeutics, Inc. announced today a licensing and collaboration agreement to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development.

Forbion Closes Third Life Sciences Fund, FCF III, Raising over USD200M

EVENTSb3cnewswire2016-04-13 13:28 Read   46

Investment focus on European, US & Canadian private companies developing novel drugs, medical devices and diagnostics

LifeSci Advisors aim for model behavior after 'serious mistake'

EVENTSfiercebiotech2016-04-13 12:50 Read   56

Picture this: You’re a life science professional, attending an after-party event at the JP Morgan Healthcare Conference in San Francisco run by investor relations firm LifeSci Advisors. You’d expect to be in the company of some serious professionals, but instead you’re surrounded by 70 svelte models in a situation that would not have been out of place on Mad Men.